Cargando…

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH

Non-alcoholic fatty liver (NAFLD) over the past years has become a metabolic pandemic linked to a collection of metabolic diseases. The nuclear receptors ERRs, REV-ERBs, RORs, FXR, PPARs, and LXR are master regulators of metabolism and liver physiology. The characterization of these nuclear receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Welch, Ryan D., Billon, Cyrielle, Losby, McKenna, Bedia-Diaz, Gonzalo, Fang, Yuanying, Avdagic, Amer, Elgendy, Bahaa, Burris, Thomas P., Griffett, Kristine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8953348/ https://www.ncbi.nlm.nih.gov/pubmed/35323681 http://dx.doi.org/10.3390/metabo12030238

Ejemplares similares

REV-ERB agonism improves liver pathology in a mouse model of NASH
por: Griffett, Kristine, et al.
Publicado: (2020)

Development of LXR inverse agonists to treat MAFLD, NASH, and other metabolic diseases
por: Griffett, Kristine, et al.
Publicado: (2023)

REV-ERB activation as a novel pharmacological approach for treating inflammatory pain
por: Makhija, Sangeet, et al.
Publicado: (2023)

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
por: Finan, Brian, et al.
Publicado: (2020)

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

Rev-erbα heterozygosity produces a dose-dependent phenotypic advantage in mice
por: Welch, Ryan D., et al.
Publicado: (2020)

Pharmacological inhibition of REV-ERB stimulates differentiation, inhibits turnover and reduces fibrosis in dystrophic muscle
por: Welch, Ryan D., et al.
Publicado: (2017)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Lifestyle modification in NAFLD/NASH: Facts and figures
por: Hallsworth, Kate, et al.
Publicado: (2019)

Diet and exercise in NAFLD/NASH: Beyond the obvious
por: Semmler, Georg, et al.
Publicado: (2021)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH
por: Colognesi, Martina, et al.
Publicado: (2020)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

Improved pathology reporting in NAFLD/NASH for clinical trials
por: Langford, Caitlin Rose, et al.
Publicado: (2022)

Deciphering the role of aberrant DNA methylation in NAFLD and NASH()
por: Vachher, Meenakshi, et al.
Publicado: (2022)

Doubled lifespan and patient‐like pathologies in progeria mice fed high‐fat diet
por: Kreienkamp, Ray, et al.
Publicado: (2018)

Inhibition of RORα/γ suppresses atherosclerosis via inhibition of both cholesterol absorption and inflammation
por: Billon, Cyrielle, et al.
Publicado: (2016)

Metabolic Characterization of a Novel RORα Knockout Mouse Model without Ataxia
por: Billon, Cyrielle, et al.
Publicado: (2017)

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
por: Griffett, Kristine, et al.
Publicado: (2015)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
por: Mahmoudi, Ali, et al.
Publicado: (2022)

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
por: Xu, Gao-Xin, et al.
Publicado: (2023)

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations
por: Adinolfi, Luigi Elio, et al.
Publicado: (2016)

SAT-LB004 Therapeutic Potential of LPCN 1144 in NAFLD and NASH
por: Baker, Jonathan, et al.
Publicado: (2019)

Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
por: Svegliati-Baroni, Gianluca, et al.
Publicado: (2020)

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
por: Carreres, Lydie, et al.
Publicado: (2021)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
por: Piras, Cristina, et al.
Publicado: (2021)

Non-Invasive Risk Stratification in NAFLD/NASH Patients for Screening EGD
por: Romano, John, et al.
Publicado: (2022)

Comprehensive Transcriptome Profiling of NAFLD- and NASH-Induced Skeletal Muscle Dysfunction
por: Guo, Mingwei, et al.
Publicado: (2022)

Therapeutic Effect of a Synthetic RORα/γ Agonist in an Animal Model of Autism
por: Wang, Yongjun, et al.
Publicado: (2015)

Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis
por: Plaza-Díaz, Julio, et al.
Publicado: (2021)

Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment
por: Dongiovanni, Paola, et al.
Publicado: (2013)

Pathophysiology of NAFLD and NASH in Experimental Models: The Role of Food Intake Regulating Peptides
por: Kořínková, L., et al.
Publicado: (2020)

Effect of exercise and diet intervention in NAFLD and NASH via GAB2 methylation
por: Wu, Na, et al.
Publicado: (2021)

Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
por: Finotti, Michele, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3ud37kpmgjek1kvhj43nvl2t8t